Logotype for Viking Therapeutics Inc

Viking Therapeutics (VKTX) investor relations material

Viking Therapeutics Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Viking Therapeutics Inc
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum summary23 Sep, 2025

Key clinical program updates

  • Lead compound VK2735, a dual GLP-1/GIP agonist, is in phase III for obesity with both subcutaneous and oral formulations advancing in trials.

  • Oral VK2735 showed up to 12% weight loss at 13 weeks in phase II, with durable effects and promising tolerability.

  • Subcutaneous VK2735 achieved nearly 15% weight loss at 13 weeks, with over 90% of efficacy retained at week 17.

  • Maintenance dosing regimens are being explored, with data supporting transition from high to lower doses while maintaining efficacy.

  • An amylin agonist is planned to enter clinical trials by late this year or early next year.

Safety, tolerability, and trial design insights

  • Most adverse events were mild to moderate, with GI events primarily occurring early and resolving quickly.

  • Slower titration rates are being used in phase III to improve tolerability, with real-world dosing expected to be individualized.

  • Placebo-controlled trials remain the regulatory standard, with patient retention aided by guaranteed access to active therapy post-trial.

  • BMI cutoffs for phase III trials align with industry standards, allowing inclusion of patients with comorbidities.

  • No regulatory path exists for maintenance-only approval; all studies focus on weight loss as the primary endpoint.

Strategic and market positioning

  • Over $800 million in cash provides runway to complete phase III trials and support aggressive development.

  • Lean operational model with just over 50 employees, leveraging external vendors for execution.

  • Direct-to-patient channels are seen as a major opportunity, reducing the need for large sales infrastructure.

  • Open to partnerships but prepared to commercialize in-house if needed, with a focus on building thoughtfully.

  • Success is defined by having multiple competitive products on the market and leveraging global direct-to-patient models.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Viking Therapeutics earnings date

Logotype for Viking Therapeutics Inc
Q3 202522 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Viking Therapeutics earnings date

Logotype for Viking Therapeutics Inc
Q3 202522 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company utilizes small-molecule drug technology to target conditions such as liver diseases, muscle disorders, and other chronic illnesses. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage